Results 91 to 100 of about 3,164,975 (245)
Investigating Effects of Hepatitis C Virus on Platelet Parameters in Hemodialysis Patients
Turkish Journal of Nephrology, 2019 AIM: In this study, we aimed to investigate the effects of hepatitis C virus on platelet parameters in hemodialysis patients. MATERIALS and METHODS: We included patients who received hemodialysis in Van region in Turkey.
İdris ŞAHİN +5 more
doaj
Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux +6 more
wiley +1 more source
Humoral Immune Response in Japanese Acute Hepatitis Patients with Hepatitis C Virus Infection
Canadian Journal of Gastroenterology, 2000 The humoral immune response to acute infection by hepatitis C virus (HCV) is not yet perfectly clear in terms of immunoglobulin (Ig) response, diversity of HCV antigen, and the relation with hepatitis severity and antibody response.
N Yamaguchi +3 more
doaj +1 more source
Phytotherapy Research, EarlyView.Schematic summary of the experimentally supported mechanism of DHL in hepatocellular carcinoma. Dehydrocostus lactone (DHL), a sesquiterpene lactone derived from Aucklandia lappa, directly engages protein tyrosine kinase 7 (PTK7), as supported by molecular docking, CETSA, and DARTS assays.
Xiwen Fan +8 more
wiley +1 more source
Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies
Rheumatology &Autoimmunity, EarlyView.In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley +1 more source
Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain
Alimentary Pharmacology &Therapeutics, EarlyView.Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez +14 more
wiley +1 more source
Revista do Instituto de Medicina Tropical de São PauloDrug users have been reported to have an increased risk for acquisition of viral hepatitis. This study aims to evaluate the prevalence of HBV and HCV infection and usefulness of saliva for HBsAg and anti-HCV detection in alcoholic patients.A total of 90 ...
Vanessa Faria Cortes +8 more
doaj +1 more source
Alimentary Pharmacology &Therapeutics, EarlyView.Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod +9 more
wiley +1 more source
INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol
BJU International, EarlyView.Background High‐risk non‐muscle‐invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette–Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease.
Ruby Lister‐Whelan +13 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source